FDA Rejects Atara Biotherapeutics' Blood Cancer Treatment, Shares Plunge
FDA Rejects Atara Biotherapeutics' Blood Cancer Treatment
Atara Biotherapeutics experienced a dramatic drop in its stock value following the FDA's rejection of its application for a new blood cancer treatment. The company's shares fell by 46.5% to $7.04, marking a significant downturn over the past six months and year.
The FDA's Complete Response Letter
The FDA issued a complete response letter to Atara, indicating that the application for its drug, Ebvallo, would not be approved in its current form. Ebvallo is designed to treat a rare form of blood cancer that occurs in patients who have undergone transplants. Importantly, the FDA's concerns were not related to the drug's safety or efficacy but stemmed from observations made during an inspection of a third-party manufacturing facility.
Atara's Next Steps
Atara Biotherapeutics has announced its intention to address the FDA's concerns and resubmit the application. The company is optimistic about receiving approval within six months of resubmission. To support these efforts, Atara has entered into a non-binding term sheet with Redmile Group, a San Francisco-based private equity manager, for funding of up to $15 million. Additionally, the company is exploring strategic options, including a potential merger or acquisition, to strengthen its position and continue its mission of bringing innovative treatments to patients.
Impact on Atara and the Pharmaceutical Industry
This development underscores the challenges faced by biotech companies in navigating the regulatory landscape and the importance of manufacturing compliance in the drug approval process. Atara's experience highlights the critical role of third-party facilities in the production of pharmaceuticals and the potential impact of regulatory decisions on company valuations and investor confidence.
As Atara works towards addressing the FDA's concerns and resubmitting its application, the pharmaceutical industry will be watching closely. The outcome of this process could have significant implications for the treatment of rare blood cancers and the broader biotech sector.